연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
1931. Dominant high expression of wild-type HSP110 defines a poor prognostic subgroup of colorectal carcinomas with microsatellite instability: a whole-section immunohistochemical analysis.
Oh HJ, Kim JH, Lee TH, Park HE, Bae JM, Lee HS, Kang GH
APMIS. 2017 Dec;125(12):1076-1083. doi: 10.1111/apm.12770. Epub 2017 Oct 3.
Link
1930. Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer.
Kim YI, Kim YJ, Paeng JC, Cheon GJ, Lee DS, Chung JK, Kang KW
Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1787-1795. doi: 10.1007/s00259-017-3748-7. Epub 2017 Jun 14.
Link
1929. Heterogeneity index evaluated by slope of linear regression on 18F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma.
Kim YI, Kim YJ, Paeng JC, Cheon GJ, Lee DS, Chung JK, Kang KW
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):1995-2003. doi: 10.1007/s00259-017-3755-8. Epub 2017 Jun 20.
Link
1928. Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors.
Sim SH, Beom SH, Ahn YO, Keam B, Kim TM, Lee SH, Kim DW, Heo DS.
Thorac Cancer. 2016 Mar;7(2):161-6. doi: 10.1111/1759-7714.12304. Epub 2015 Aug 28.
Link
1927. Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers.
Lee JH, Zhao XM, Yoon I, Lee JY, Kwon NH, Wang YY, Lee KM, Lee M4, Kim J, Moon HG, In Y, Hao JK, Park KM, Noh DY, Han WS, Kim S.
Cell Discov. 2016 Aug 30;2:16025. doi: 10.1038/celldisc.2016.25. eCollection 2016.
Link
1926. Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.
Lee ES, Han WS, Kim MK, Kim J, Yoo TK, Lee MH, Lee KH, Kim TY, Moon HG, Im SA, Noh DY, Lee ES.
BMC Cancer. 2016 Jul 7;16:430. doi: 10.1186/s12885-016-2423-x.
Link
1925. Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer.
Lee KM, Lee M, Lee J, Kim SW, Moon HG, Noh DY, Han WS.
Oncotarget. 2016 Jun 21;7(25):38500-38512. doi: 10.18632/oncotarget.9522.
Link
1924. Oncologic Safety of Immediate Breast Reconstruction for Invasive Breast Cancer Patients: A Matched Case Control Study.
Park SH, Han WS, Yoo TK, Lee HB, Jin US, Chang H, Minn KW, Noh DY.
J Breast Cancer. 2016 Mar;19(1):68-75. doi: 10.4048/jbc.2016.19.1.68. Epub 2016 Mar 25.
Link
1923. Delay of Treatment Initiation Does Not Adversely Affect Survival Outcome in Breast Cancer.
Yoo TK, Han WS, Moon HG, Kim J, Lee JW, Kim MK, Lee E, Kim J, Noh DY.
Cancer Res Treat. 2016 Jul;48(3):962-9. doi: 10.4143/crt.2015.173. Epub 2015 Oct 22.
Link
1922. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.
Lim Y, Bang JI, Han SW, Paeng JC, Lee KH, Kim JH, Kang GH, Jeong SY, Park KJ, Kim TY.
Eur J Nucl Med Mol Imaging. 2016 Nov 25. [Epub ahead of print]
Link